021-51111890
购物车（）
sales@molnova.cn
OBP-801
CAS No. 328548-11-4
OBP-801 ( OBP801;YM 753;Spiruchostatin A )
产品货号. M14075 CAS No. 328548-11-4
OBP-801 (YM 753;Spiruchostatin A) is a novel cyclic-peptide-based HDAC inhibitor with IC50 of 2 nM.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥13527 | 有现货 |
|
| 50MG | ￥27378 | 有现货 |
|
| 100MG | ￥37260 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称OBP-801
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述OBP-801 (YM 753;Spiruchostatin A) is a novel cyclic-peptide-based HDAC inhibitor with IC50 of 2 nM.
-
产品描述OBP-801 (YM 753;Spiruchostatin A) is a novel cyclic-peptide-based HDAC inhibitor with IC50 of 2 nM; significantly inhibits the cell growth on comparison with each agent alone and synergistically increased apoptosis with the induction of Bim; significantly suppresses tumor growth in vivo.Kidney Cancer Phase 1 Clinical
-
同义词OBP801;YM 753;Spiruchostatin A
-
通路Cell Cycle/DNA Damage
-
靶点HDAC
-
受体HDAC
-
研究领域Cancer
-
适应症Kidney Cancer
化学信息
-
CAS Number328548-11-4
-
分子量473.60
-
分子式C20H31N3O6S2
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESO=C1C[C@H](O2)/C=C/CCSSC[C@@H](NC([C@@H](C)N1)=O)C(N[C@H](C(C)C)[C@@H](O)CC2=O)=O
-
化学全称(1S,5S,6R,9S,20R,E)-5-hydroxy-6-isopropyl-20-methyl-2-oxa-11,12-dithia-7,19,22-triazabicyclo[7.7.6]docos-15-ene-3,8,18,21-tetraone
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Shindoh N, et al. Int J Oncol. 2008 Mar;32(3):545-55.
2. Yoshioka T, et al. Gynecol Oncol. 2013 May;129(2):425-32.
3. Furutani A, et al. Oncol Res. 2014;21(5):281-6.
4. Akiyama M, et al. Oncol Res. 2017 Sep 21;25(8):1245-1252.
2. Yoshioka T, et al. Gynecol Oncol. 2013 May;129(2):425-32.
3. Furutani A, et al. Oncol Res. 2014;21(5):281-6.
4. Akiyama M, et al. Oncol Res. 2017 Sep 21;25(8):1245-1252.
产品手册
关联产品
-
Class I and IIB HDAC...
Class I and IIB HDAC inhibitor 42 is a novel potent, selective class I and IIB inhibitor.
-
ACY-775
ACY-775 (ACY775) is a potent and specific HDAC6 inhibitor (IC50=7.5 nM) with improved brain bioavailability.
-
Quisinostat
Quisinostat (JNJ-26481585) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11.
